论文部分内容阅读
目的:评价扩张型心肌病的远期预后。方法:扩张型心肌病患者63例,给予强心、利尿、β受体阻滞剂、血管紧张素转化酶抑制剂及中药生脉(参麦)复方制剂治疗,定期随访,随访时间3～13年。随访项目包括:心功能改善情况、体力活动适应程度、院外服药治疗、再次入院次数,死亡,了解并登记死亡原因。结果:63例中随访3～5年16例,5～10年35例,10年以上12例,平均随访时间6.1年。随访期间死亡18例(病死率28.6%);存活45例,存活者患病时间2～15年,其中28例能从事一般正常劳动及工作(62.2%),生活可自理者10例(22.2%)。结论:由于治疗方案的改进,特别是中西医结合药物的应用,使扩张型心肌病患者的预后改善,平均存活时间延长,多数患者的生存质量提高。
Objective: To evaluate the long-term prognosis of dilated cardiomyopathy. Methods: 63 patients with dilated cardiomyopathy were treated with cardiotomy, diuretic, β-blocker, angiotensin converting enzyme inhibitor and traditional Chinese medicine Shengmai (Shenmai) compound. The patients were followed up for a period of 3 to 13 year. The follow-up items included: improvement of cardiac function, degree of physical activity adaptation, outpatient medication, number of hospitalizations again, death, understanding and registration of the cause of death. Results: 63 cases were followed up for 3 to 5 years in 16 cases, 5 to 10 years in 35 cases, more than 10 years in 12 cases, the average follow-up time was 6.1 years. There were 18 deaths (28.6%) during the follow-up period; 45 survived and 2 to 15 years survivors, of whom 28 were able to take part in normal work and work (62.2%), and 10 (22.2% ). Conclusion: Due to the improvement of treatment regimen, especially the combination of traditional Chinese and Western medicine, the prognosis of patients with dilated cardiomyopathy is improved, the average survival time is prolonged, and the quality of life of most patients is improved.